| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -20,908 | -2,222 | -22,795 | -67,175 |
| Depreciation, amortization, and impairment | 13,493 | 13,078 | 12,941 | 51,302 |
| Inventory reserve expenses | 2,900 | 3,049 | 2,383 | 25,393 |
| Amortization of operating lease assets, debt costs, and other assets | 1,058 | 1,975 | 1,582 | 2,377 |
| Provision for expected credit losses | 719 | -211 | 629 | 1,837 |
| Deferred income taxes | 93 | -110 | 321 | 12 |
| Share-based compensation expense | 6,533 | 7,214 | 7,181 | 14,293 |
| Loss on disposal of fixed assets | -331 | -279 | -280 | -581 |
| Change in valuation of investment securities | 16 | 7 | 10 | 31 |
| Change in fair value of contingent consideration | 750 | 660 | -427 | -1,373 |
| Other | 178 | -711 | -2,315 | 1,188 |
| Accounts receivable | 2,964 | 4,714 | 1,958 | -5,089 |
| Inventories | 8,845 | 1,279 | 3,579 | 5,890 |
| Prepaid expenses and other current assets | 1,459 | 4,723 | -1,191 | 394 |
| Accounts payable | -4,368 | 8,255 | 3,482 | -9,138 |
| Other current liabilities | -5,221 | 6,784 | 12,711 | -21,763 |
| Contingent consideration milestone payment | NaN | 0 | 1,340 | NaN |
| Other long-term assets and liabilities | -472 | 1,042 | 2,505 | 684 |
| Net cash used in operating activities | -17,610 | 27,697 | 12,402 | -6,752 |
| Capital expenditures | 10,661 | 10,877 | 9,904 | 13,845 |
| Other investing activities | -146 | -6 | -10 | -12 |
| Net cash used in investing activities | -10,515 | -10,871 | -9,894 | -13,833 |
| Proceeds from issuance of common shares | NaN | 2,839 | 36 | 3,054 |
| Payments related to withholdings for share-based compensation | NaN | 264 | 9 | 159 |
| Contingent consideration milestone payment | NaN | 0 | 4,990 | NaN |
| Payments related to finance lease obligation | 31 | 198 | 189 | 375 |
| Borrowings under credit facility | 64,025 | NaN | NaN | NaN |
| Payment of debt issuance costs and other financing activities | 24 | 0 | 0 | 531 |
| Net cash provided by (used in) financing activities | 63,970 | 2,377 | -5,152 | 1,989 |
| Effect of exchange rate changes on cash | -90 | -34 | -99 | 1,547 |
| Net change in cash and cash equivalents | 35,755 | 19,169 | -2,743 | -17,049 |
| Cash, cash equivalents, and restricted cash at the beginning of period | 85,115 | 65,946 | 85,738 | NaN |
| Cash, cash equivalents, and restricted cash at the end of period | 120,870 | 85,115 | 65,946 | NaN |
Orthofix Medical Inc. (OFIX)
Orthofix Medical Inc. (OFIX)